PTEN: From pathology to biology

Trends in Cell Biology

Volumn 13, Issue 9, 2003, Pages 478-483

  Sulis, Maria Luisa ^a,b   Parsons, Ramon ^a  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; S6 KINASE;

BIOLOGY; CELL FUNCTION; CELL MIGRATION; DISEASE COURSE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE TARGETING; INTRACELLULAR SPACE; MULTIGENE FAMILY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0142011466     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(03)00175-2     Document Type: Review

References (70)

1. Cantley L.C., Neel B.G. New insights into tumour suppression: PTEN suppresses tumour formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4240-4245.
2. Simpson L., Parsons R. PTEN: life as a tumour suppressor. Exp. Cell Res. 264:2001;29-41.
3. Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:1999;125-128.
4. Di Cristofano, A. and Pandolfi, P.P. (2000) The multiple roles of PTEN in tumour suppression. Cell 100, 387-390.
5. Maehama T., Dixon J.E. The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:1998;13375-13378.
6. Lioubin M.N., et al. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 10:1996;1084-1095.
7. Lee J.O., et al. Crystal structure of the PTEN tumour suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 99:1999;323-334.
8. Li L., et al. A family of putative tumour suppressors is structurally and functionally conserved in humans and yeast. J. Biol. Chem. 272:1997;29403-29406.
9. Chen H., et al. A testis-specific gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps to the pericentromeric region of human chromosomes 21 and 13, and to chromosomes 15, 22, and Y. Hum. Genet. 105:1999;399-409.
10. Wu Y., et al. PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumour suppressor lipid phosphatase. J. Biol. Chem. 276:2001;21745-21753.
11. Walker S.M., et al. TPIP: a novel phosphoinositide 3-phosphatase. Biochem. J. 360:2001;277-283.
12. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
13. Risinger J.I., et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57:1997;4736-4738.
14. Tashiro H., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57:1997;3935-3940.
15. Steck P.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
16. Whang Y.E., et al. Inactivation of the tumour suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. U. S. A. 95:1998;5246-5250.
17. Soria J.C., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8:2002;1178-1184.
18. Podsypanina K., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1563-1568.
19. Kwabi-Addo B., et al. Haploinsufficiency of the Pten tumour suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11563-11568.
20. Suzuki A., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 14:2001;523-534.
21. Crackower M.A., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 110:2002;737-749.
22. Kwon C.H., et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat. Genet. 29:2001;404-411.
23. Li G., et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 129:2002;4159-4170.
24. Backman S.A., et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29:2001;396-403.
25. Kimura T., et al. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development. 130:2003;1691-1700.
26. Ashcroft M., et al. Phosphorylation of HDM2 by Akt. Oncogene. 21:2002;1955-1962.
27. Oldham S., et al. The Drosophila insulin/IGF receptor controls growth and size by modulating PtdInsP(3) levels. Development. 129:2002;4103-4109.
28. Gao X., et al. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 221:2000;404-418.
29. Scanga S.E., et al. The conserved PI3′K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene. 19:2000;3971-3977.
30. Huang H., et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. Development. 126:1999;5365-5372.
31. Das S., et al. Membrane-binding and activation mechanism of PTEN. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7491-7496.
32. Deichmann M., et al. PTEN/MMAC1 expression in melanoma resection specimens. Br. J. Cancer. 87:2002;1431-1436.
33. McMenamin M.E., et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:1999;4291-4296.
34. Lachyankar M.B., et al. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 20:2000;1404-1413.
35. Sano T., et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59:1999;1820-1824.
36. Gimm O., et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumours. Am. J. Pathol. 156:2000;1693-1700.
37. Wu X., et al. Evidence for regulation of the PTEN tumour suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4233-4238.
38. Ginn-Pease M.E., Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res. 63:2003;282-286.
39. Perren A., et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumours compared to normal islet cells. Am. J. Pathol. 157:2000;1097-1103.
40. Whiteman D.C., et al. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer. 99:2002;63-67.
41. Tamura M., et al. Inhibition of cell migration, spreading, and focal adhesions by tumour suppressor PTEN. Science. 280:1998;1614-1617.
42. Liliental J., et al. Genetic deletion of the Pten tumour suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 10:2000;401-404.
43. Parent C.A., et al. G protein signaling events are activated at the leading edge of chemotactic cells. Cell. 95:1998;81-91.
44. Servant G., et al. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science. 287:2000;1037-1040.
45. Comer F.I., Parent C.A. PI 3-kinases and PTEN: how opposites chemoattract. Cell. 109:2002;541-544.
46. Chung C.Y., et al. Control of cell polarity and chemotaxis by Akt/PKB and PI3 kinase through the regulation of PAKa. Mol. Cell. 7:2001;937-947.
47. Funamoto S., et al. Role of phosphatidylinositol 3′ kinase and a downstream pleckstrin homology domain-containing protein in controlling chemotaxis in dictyostelium. J. Cell Biol. 153:2001;795-810.
48. Funamoto S., et al. Spatial and temporal regulation of 3-phosphoinositides by PI 3-kinase and PTEN mediates chemotaxis. Cell. 109:2002;611-623.
49. Iijima M., Devreotes P. Tumour suppressor PTEN mediates sensing of chemoattractant gradients. Cell. 109:2002;599-610.
50. Iijima M., et al. Temporal and spatial regulation of chemotaxis. Dev. Cell. 3:2002;469-478.
51. Stocker H., et al. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science. 295:2002;2088-2091.
52. Ogg S., Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell. 2:1998;887-893.
53. Cho K.S., et al. Drosophila phosphoinositide-dependent kinase-1 regulates apoptosis and growth via the phosphoinositide 3-kinase-dependent signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6144-6149.
54. Paradis S., et al. A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans. Genes Dev. 13:1999;1438-1452.
55. Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 401:1999;86-90.
56. Zhong H., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumour angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545.
57. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
58. Sears R., et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2000;2501-2514.
59. Cross D.A., et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:1995;785-789.
60. Cardone M.H., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321.
61. Datta S.R., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
62. Zhou B.P., et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:2001;973-982.
63. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11598-11603.
64. Mayo L.D., et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277:2002;5484-5489.
65. Stambolic V., et al. Regulation of PTEN transcription by p53. Mol. Cell. 8:2001;317-325.
66. Freeman D.J., et al. PTEN tumour suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 3:2003;117-130.
67. Lu Y., et al. The PTEN/MMAC1/TEP tumour suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 18:1999;7034-7045.
68. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657.
69. Radimerski T., et al. Lethality of Drosophila lacking TSC tumour suppressor function rescued by reducing dS6K signaling. Genes Dev. 16:2002;2627-2632.
70. Majumder P.K., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc. Natl. Acad. Sci. U. S. A. 100:2003;7841-7846.